Fibroblast activation protein targeted imaging and therapy (Editors: Philipp Backhaus, Dr.med. & Imke Schatka, Dr.med.)
Molecular Imaging Innovations in Neurology and Neuro-Oncology (Editors: Francesco Cicone, PhD & Antoine Verger, PhD)
Aims and scope
EJNMMI Research publishes new basic, translational and clinical research in the field of nuclear medicine and molecular imaging.
Regular features include original research articles, short communication of preliminary data on innovative research, interesting case reports, editorials, and letters to the editor.
Educational articles on basic sciences, fundamental aspects and controversy related to pre-clinical and clinical research or ethical aspects of research are also welcome.
The journal also considers preliminary Research Articles or short communications that include novel findings, methods or radiopharmaceuticals with a high potential but limited data available, worth a preliminary information.
Timely reviews provide updates on current applications, issues in imaging research and translational aspects of nuclear medicine and molecular imaging technologies.
Topics include but not limited to innovative research covering all aspects of molecular imaging, e.g. radiopharmaceutical approaches with a high potential of clinical impact, important aspects in image reconstruction and accuracy, or within the theranostic field with therapy combinations or incorporation of artificial intelligence in image generation or interpretation.
Articles
-
-
Test-retest repeatability of quantitative organ and tissue uptake using 20-minute dynamic multiparametric whole-body [18F]FDG PET/CT in patients with type 2 diabetes
-
Deep learning for Parkinson’s disease classification using multimodal and multi-sequences PET/MR images
-
PSMA-expressing, fluciclovine-negative vertebral hemangioma
-
Quantitative 177Lu-DOTATATE SPECT/CT is predictive of 6-month PRRT morphological response in midgut neuroendocrine tumors: a pilot study
-
Nanobody: a promising toolkit for molecular imaging and disease therapy
-
Anaesthesia and physiological monitoring during in vivo imaging of laboratory rodents: considerations on experimental outcomes and animal welfare
-
Gastrointestinal transit measurements in mice with 99mTc-DTPA-labeled activated charcoal using NanoSPECT-CT
-
About inflammation and infection
-
Synthesis and preclinical evaluation of DOTAGA-conjugated PSMA ligands for functional imaging and endoradiotherapy of prostate cancer
Thematic Collections: Call for Papers
Need help with APC funding?
We offer a free open access support service to make it easier for you to discover and apply for article-processing charge (APC) funding. Learn more here.
Check if your institution is a member
More than 500 institutions have partnered with BMC through the membership program. As an affiliated Author from a member institution, you may be entitled to submit your manuscript without paying the article processing charge (APC) or with a discount. Check here if your institution is a member!
Large prospective randomized trials are needed, to advance the application of new radiopharmaceuticals into clinical guidelines and daily routine. To generate the hypothesis and find novel approaches that can be tested in such highly complex and regulated trials, smaller scale “proof of mechanism” or phase 0 studies, preclinical research with a strong clinical focus, as well as analysis on retrospective data are needed. This will be the focus and strength of EJNMMI Research, at the intercept between clinical nuclear medicine, radiochemistry, biology, physics, drug development and radiation oncology.
This journal has been launched by Springer and is a companion journal to the EJNMMI family. Authors of papers with a focus on nuclear medicine, whose manuscript despite high quality is not accepted in the mother journal can submit to this daughter journal. Besides regular papers the journal gives the possibility to publish reviews, educational papers guidelines and short communications.
By this combination of different articles, I hope to establish a unique platform for nuclear medicine, with the potential to reach the important audience in clinic as well as in basic science.
Irene A. Burger, Editor-in-Chief
The EJNMMI Journal Family
Additional information about the EJNMMI group of journals can be found on the EJNMMI Journal Family webpage.
Annual Journal Metrics
-
Citation Impact 2023
Journal Impact Factor: 3.1
5-year Journal Impact Factor: 3.0
Source Normalized Impact per Paper (SNIP): 0.948
SCImago Journal Rank (SJR): 0.916Speed 2024
Submission to first editorial decision (median days): 11
Submission to acceptance (median days): 92Usage 2024
Downloads: 665,703
Altmetric mentions: 109
- ISSN: 2191-219X (electronic)